Gilead Sciences (GILD) Total Liabilities (2009 - 2026)
Gilead Sciences' (GILD) quarterly Total Liabilities came in at $56.3 billion in Q1 2026, little changed YoY from $56.4 billion in Q1 2025, and down 4.65% on a QoQ basis from $59.0 billion in Q4 2025.
Gilead Sciences (GILD) Total Liabilities (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Total Liabilities data on file, last reported at $56.3 billion in Q1 2026.
- Quarterly Total Liabilities changed 0.28% year-over-year to $56.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.3 billion (changed 0.28% YoY) and the FY2025 annual result came in at $59.0 billion, changed 0.05% from the prior year.
- Total Liabilities slipped to $56.3 billion in Q1 2026, from $59.0 billion in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $63.2 billion in Q4 2022 to a low of $53.6 billion in Q2 2024.
- A 5-year average of $59.4 billion and a median of $59.0 billion in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities declined 14.05% — and 2025, when it advanced 7.35%.
- Tracing GILD's Total Liabilities over 5 years: stood at $63.2 billion in 2022, then fell by 1.66% to $62.1 billion in 2023, then dropped by 5.04% to $59.0 billion in 2024, then climbed by 0.05% to $59.0 billion in 2025, then declined by 4.65% to $56.3 billion in 2026.
- The last three Total Liabilities figures came in at $56.3 billion (Q1 2026), $59.0 billion (Q4 2025), and $58.5 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.36 Bn |
| Mar 31, 2026 | 56.28 Bn |
| Dec 31, 2025 | 59.02 Bn |
| Sep 30, 2025 | 58.53 Bn |
| Jun 30, 2025 | 55.72 Bn |
| Mar 31, 2025 | 56.43 Bn |
| Dec 31, 2024 | 59.00 Bn |
| Sep 30, 2024 | 54.53 Bn |
| Jun 30, 2024 | 53.58 Bn |
| Mar 31, 2024 | 56.29 Bn |
| Dec 31, 2023 | 62.13 Bn |
| Sep 30, 2023 | 62.37 Bn |
| Jun 30, 2023 | 62.34 Bn |
| Mar 31, 2023 | 61.88 Bn |
| Dec 31, 2022 | 63.17 Bn |
| Sep 30, 2022 | 62.56 Bn |
| Jun 30, 2022 | 62.87 Bn |
| Mar 31, 2022 | 63.08 Bn |
| Dec 31, 2021 | 67.95 Bn |
| Sep 30, 2021 | 67.10 Bn |